Grant: Collaborative Research and Development Grants
University of Ottawa
$90,000.00
Viral sensitizer technology for increasing yield of vaccines produced in cell culture
EF 2019-20
Résumé
Vaccination is the most effective way to prevent deadly human diseases. Despite this, global vaccination coverage continues to be a challenge and concern for public health. A major barrier to maximizing this coverage remains the ability to reliably produce sufficient vaccine doses in a timely manner. This is highlighted (but not restricted to) the shortcomings of the 2009 pandemic H1N1 vaccination campaign and the more recent Yellow Fever crisis in Angola. As a solution to this, we have discovered and developed viral sensitizer technology (VST), a growing collection of compounds with the potential to improve industrial-scale vaccine production with little to no added infrastructure costs. We have successfully demonstrated that VST can enhance by over 10-fold the production of viral vaccines. As a result, we have entered into collaborations with companies such as Sanofi Pasteur, a world leader in vaccine manufacturing, to evaluate the impact of VST for some of their products. Based on promising results, we now aim to determine whether VST can boost the production of Influenza, Rotavirus, and Yellow Fever virus vaccines. Specifically, we aim to (1) evaluate VST impact on yields from cell-based culture of Influenza, Rotavirus, and Yellow Fever vaccine strains (2) determine the optimal formulation for VST industrial/scale-up implementation and (3) assess the quality of the resulting vaccine. To achieve this, our experienced team will develop novel high throughput assays to rapidly identify promising viral sensitizer formulations. We will work with Sanofi Pasteur to implement VST in scale-up processes. In parallel, we will synthesize small molecule derivatives of viral sensitizers that we will use to develop mass spectrometry methods to track viral sensitizers, identify their metabolites, and follow them through the vaccine manufacturing process. Short term, this project will help train upwards of 30 highly qualified personnel in Canada. Long term, we expect that VST will reduce the cost and increase the availability of vaccines globally. Sanofi Pasteur, a global player with major R&D presence in Canada, is a strategic partner in this endeavour that will maximize technological and economic impacts.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
501856-2016
Name nom
Diallo, JeanSimon
Department département
Biochemistry, Microbiology and Immunology
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2016
Award amount
90000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
5202
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Virology
Research subject fr
Virologie
Installment
inst:3 - 3
Partie
3
Nb partie
3
Application title
Viral sensitizer technology for increasing yield of vaccines produced in cell culture
Keyword
NSERC
Application summary
Vaccination is the most effective way to prevent deadly human diseases. Despite this, global vaccination coverage continues to be a challenge and concern for public health. A major barrier to maximizing this coverage remains the ability to reliably produce sufficient vaccine doses in a timely manner. This is highlighted (but not restricted to) the shortcomings of the 2009 pandemic H1N1 vaccination campaign and the more recent Yellow Fever crisis in Angola. As a solution to this, we have discovered and developed viral sensitizer technology (VST), a growing collection of compounds with the potential to improve industrial-scale vaccine production with little to no added infrastructure costs. We have successfully demonstrated that VST can enhance by over 10-fold the production of viral vaccines. As a result, we have entered into collaborations with companies such as Sanofi Pasteur, a world leader in vaccine manufacturing, to evaluate the impact of VST for some of their products. Based on promising results, we now aim to determine whether VST can boost the production of Influenza, Rotavirus, and Yellow Fever virus vaccines. Specifically, we aim to (1) evaluate VST impact on yields from cell-based culture of Influenza, Rotavirus, and Yellow Fever vaccine strains (2) determine the optimal formulation for VST industrial/scale-up implementation and (3) assess the quality of the resulting vaccine. To achieve this, our experienced team will develop novel high throughput assays to rapidly identify promising viral sensitizer formulations. We will work with Sanofi Pasteur to implement VST in scale-up processes. In parallel, we will synthesize small molecule derivatives of viral sensitizers that we will use to develop mass spectrometry methods to track viral sensitizers, identify their metabolites, and follow them through the vaccine manufacturing process. Short term, this project will help train upwards of 30 highly qualified personnel in Canada. Long term, we expect that VST will reduce the cost and increase the availability of vaccines globally. Sanofi Pasteur, a global player with major R&D presence in Canada, is a strategic partner in this endeavour that will maximize technological and economic impacts.